Agency IQ

JUNE 16, 2023

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. The rule, will also, if finalized, address communication with State boards of pharmacy. The final rule will amend the administrative destruction provisions in 21 CFR 1.94

Regulations 40

Regulations FDA Science Production 40

Drug & Device Law

JULY 24, 2023

at *6 (plaintiff “has documents and formularies reaching back to only 2009”). the relationship between [plaintiff] and its pharmacy benefit manager. . . Apparently, massive loss of evidence was merely a “usual and customary service” of pharmacy benefit mangers nationwide. According to Plaintiffs’ expert. . ., 555, 565 (E.D.

Testimonials 52

Testimonials Pharmacy FDA Doctors 52

Drug & Device Law

FEBRUARY 20, 2023

In at least the short term, a popular pain reliever would have to be removed from pharmacies. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. were not approved by the FDA in 2009. . . . His testimony is thus irrelevant and inadmissible. This would run counter to. . .

FDA 59

FDA FDA Approval Testimonials Vaccine 59